Shots:
- The US FDA has approved penpulimab-kcqx + CT (cisplatin/carboplatin + gemcitabine) as 1L treatment for recurrent or metastatic non-keratinizing NPC in adults, & as monotx. for those with metastatic non-keratinizing NPC progressing on/after Pt-based CT & ≥1L prior therapy
- Approval was supported by 2 BLA submissions based on international P-III (AK105-304) trial & pivotal AK105-202 study assessing penpulimab-kcqx across two stages of metastatic NPC; data to be presented at AACR 2025
- Penpulimab-kcqx (PD-1 mAb) was initially developed by Akeso, with subsequent development & commercialization handled via a joint venture with Chia Tai-Tianqing Pharmaceutical Group
Ref: PRNewswire | Image: Akeso
Related News:- Akeso Reports First Patient Enrollment in P-III Study of Ivonescimab + CT to Treat Triple-Negative Breast Cancer (TNBC) in China
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click Here for Full Press Release
